The treatment recommendation is specifically for eligible adults for whom surgery or radiation treatment is not appropriate. NICE’s decision means eligible patients will be able to gain full NHS access to the drug in England via routine commissioning.
Around 28,000 people are diagnosed with CSCC every year, and out of this group, an estimated 2% will be at risk of developing metastatic disease.
As the second most common skin cancer in the UK, CSCC accounts for 23% of all non-melanoma skin cancers. Diagnoses of non-melanoma skin cancer are increasing and have been forecast to continue until 2040…
